Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHF8 | Q9UPP1 | 5/20 | 0.58 |
| ▸ | HPGDS | O60760 | 1/20 | 0.56 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 5/20 | 0.51 |
| ▸ | KDM5A | P29375 | 3/20 | 0.51 |
| ▸ | KDM4A | O75164 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18579255 | 0.79 | KDM5B (0.61) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 | |
| SCHEMBL1346083 | 0.76 | HPGDS (0.77) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 | |
| SCHEMBL18579507 | 0.74 | KDM4C (0.65) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 | |
| SCHEMBL19936854 | 0.74 | HPGDS (0.51) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 | |
| SCHEMBL21429720 | 0.73 | HPGDS (0.59) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 | |
| SCHEMBL16116394 | 0.72 | HPGDS (0.51) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 | |
| SCHEMBL2315630 | 0.72 | HPGDS (1.00) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 | |
| SCHEMBL19383323 | 0.71 | PHF8 (0.55) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 | |
| SCHEMBL28714930 | 0.71 | HPGDS (0.64) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 | |
| SCHEMBL3611128 | 0.71 | CYP2E1 (1.00) | PHF8HPGDSCYP2E1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111936496-B | Heterocyclic compounds useful as medicaments | 马萨里克大学 | 2023-12-29 | — | — | CN | disclosed |
| US-11498920-B2 | 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors | MASARYKOVA UNIVERZITA (CZ) | 2022-11-15 | — | — | US | disclosed |
| EP-3774795-B1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | UNIV MASARYKOVA (CZ) | 2022-03-16 | — | — | EP | disclosed |
| EP-3774795-B1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | UNIV MASARYKOVA (CZ) | 2022-03-16 | — | — | EP | disclosed |
| US-20210040086-A1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | MASARYKOVA UNIVERZITA (CZ) | 2021-02-11 | — | — | US | disclosed |
| US-20210040086-A1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | MASARYKOVA UNIVERZITA (CZ) | 2021-02-11 | — | — | US | disclosed |
| CN-111936496-A | Use of 4- (1H-imidazol-5-yl) -1H-pyrrolo [2,3-B ] pyridine for the treatment of leukemias, lymphomas and solid tumors | 马萨里克大学 | 2020-11-13 | — | — | CN | disclosed |
| WO-2019185631-A1 | 4—(1H— IMIDAZOL— 5— YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | MASARYKOVA UNIVERZITA (CZ) | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11498920-B2 | 4-(1H-imidazol-5-yl)-1H-pyrrolo[2, 3-b] pyridines for use in the treatment of leukaemias, lymphomas and solid tumors | MALT1, BCL3, MCL1 | PHF8 1222/4885HPGDS 319/4885CYP2E1 1877/4885 |
| US-20210040086-A1 | 4-(1H- IMIDAZOL- 5- YL) -1H-PYRROLO [2, 3-B] PYRIDINES FOR USE IN THE TREATMENT OF LEUKAEMIAS, LYMPHOMAS AND SOLID TUMORS | MALT1, BCL3, MCL1 | PHF8 1222/4885HPGDS 319/4885CYP2E1 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.